Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.

Shares were up 4.6% to $48.18 in premarket trading.

The medical-device maker on Wednesday posted a profit of $907 million, or 61 cents a share, compared with $797 million, or 53 cents a share, a year earlier.

Stripping out certain one-time items, adjusted per-share earnings were 86 cents, ahead of the 83 cents anticipated by analysts, according to FactSet.

Revenue rose 7.5% to $5.44 billion. Analysts surveyed by FactSet forecast revenue of $5.36 billion.

MedSurg, the company's business focused on gastrointestinal and urological devices, saw sales rise 5.9% in the quarter, while its cardiovascular segment's revenue increased 8.3%.

Boston Scientific now expects annual sales will grow 5.5% to 6.5%, down from 7% to 8.5% previously. It also cut its adjusted earnings-per-share guidance to a range of $3.28 to $3.32, from the prior $3.34 to $3.41.

For the current third quarter, the Marlborough, Mass., company projects revenue will increase 3% to 5%, with adjusted earnings per share estimated at 80 cents to 82 cents. Analysts forecast 84 cents a share.

Earlier this week, Boston Scientific said it planned to lay off staff as part of a new restructuring plan. It expects to incur pretax charges of about $700 million to $800 million from the restructuring, it said on Monday.

The company said it is aiming to optimize supply chains by transferring some production lines to different facilities. It also wants to streamline its organizational structure, it said. The plan is scheduled to be completed by the end of 2029.